Research Article
Prognostic Value of Plasma Pentraxin-3 Levels in Patients with Stable Coronary Artery Disease after Drug-Eluting Stent Implantation
Table 2
Clinical characteristic according to median value of PTX3 at 24 h after PCI.
| | | PTX3 < 4.384 ng/mL ( = 299) | PTX3 > 4.384 ng/mL ( = 297) | value |
| | Age (years) | 66.27 ± 8.5 | 65.53 ± 7.8 | 0.269 | | Male, (%) | 242 (80.9) | 225 (75.8) | 0.136 | | CCSA class > II, (%) | 86 (28.8) | 98 (33.0) | 0.288 | | LVEF < 50%, (%) | 76 (25.4) | 102 (34.3) | 0.020 | | Diabetes mellitus, (%) | 38 (12.7) | 54 (18.2) | 0.070 | | Hypertension, (%) | 163 (54.5) | 156 (52.5) | 0.408 | | Hyperlipidemia, (%) | 94 (31.4) | 84 (28.3) | 0.726 | | Current smoking, (%) | 98 (32.8) | 98 (33.0) | 0.248 | | PTX3 before PCI (ng/mL) | 3.11 ± 0.62 | 3.13 ± 0.64 | 0.699 | | cTnI (ng/mL) | 0.205 ± 0.11 | 0.251 ± 0.16 | 0.000 | | HsCRP (ng/mL) | 3.045 ± 1.12 | 3.496 ± 1.12 | 0.000 | | In-hospital therapy | | | | | Aspirin, (%) | 299 (100) | 297 (100) | | | Clopidogrel, (%) | 299 (100) | 297 (100) | | | -Blockers, (%) | 238 (79.6) | 227 (76.4) | 0.374 | | ACE-I or ARB, (%) | 272 (91.0) | 260 (87.5) | 0.188 | | Statins, (%) | 299 (100) | 297 (100) | | | Types of DES | | | | | Sirolimus, (%) | 197 (65.9) | 193 (65.0) | 0.863 | | Zotarolimus, (%) | 66 (22.1) | 64 (21.5) | 0.921 | | Paclitaxel, (%) | 29 (9.7) | 34 (11.4) | 0.508 | | Others, (%) | 7 (2.3) | 6 (2.0) | 0.999 | | Multiple stents, (%) | 105 (19.5) | 133 (32.9) | 0.024 |
|
|
Abbreviations as in Table 1.
|
